CSL Stock

CSL OCF/Debt

The Operating Cash Flow to Debt Ratio of CSL (CSL.AX) as of Sep 15, 2026 is 30.97 %. In the previous year, Operating Cash Flow to Debt Ratio was 22.69 % — a change of 36.51% (higher).

OCF/Debt

30.97 %

YoY

36.51%

Last updated:

Operating Cash Flow to Debt Ratio of CSL is 2026 30.97 % . Operating Cash Flow to Debt Ratio of CSL was 2025 22.69 % . It decreases by 36.51% higher compared to the previous year.

The CSL OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
43.36 USD
Jan 1, 2019
35.27 USD
Jan 1, 2020
60.16 USD
Jan 1, 2021
83.18 USD
Jan 1, 2022
39.43 USD
Jan 1, 2023
31.94 USD
Jan 1, 2024
22.69 USD
Jan 1, 2025
30.97 USD
The CSL OCF/Debt history
YEAROCF/DebtYoY
30.97 %+36.51%
22.69 %-28.97%
31.94 %-18.99%
39.43 %-52.60%
83.18 %+38.25%
60.16 %+70.60%
35.27 %-18.67%
43.36 %+38.28%
31.36 %-18.43%
38.44 %-35.70%
59.78 %-18.97%
73.78 %
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Operating Cash Flow to Debt Ratio of CSL is 30.97 % in 2026.

Operating Cash Flow to Debt Ratio of CSL changed from 22.69 % to 30.97 %, representing a 36.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio CSL since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's CSL with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — CSL

All Key Metrics — CSL